|
SIRO Clinpharm collaborates with Mediscis, broadens Early Phase Drug development
expertise.
Pact will widen SIRO’s reach in Western Europe Clinical Research market.
Mumbai, India, Nov 13, 2009 - SIRO Clinpharm, a global Contract Research Organization (CRO) with a base in India,
US, Europe and Israel today announced their alliance with Mediscis, an early Drug Development company based in
Poitiers and La Rochelle, France.
Mediscis is an established expert in GCP compliant early phase drug development services including clinical trials
and bioanalytics; SIRO offers expertise across all study phases for the pharmaceutical and biotech industry.
“This will be an important collaboration for both the parties as they stand to gain access to each others’ core
competencies”, said Scott Spector, President, Strategic Operations, Europe. “This alliance will allow us to
provide additional services to our global clients to support their clinical development plans.”
“Following the acquisition of Omega Mediation Clinical Research Services, SIRO was able to establish a footprint
in the European clinical research market. We envision becoming a leading drug development solutions provider by
delivering compelling value propositions to the global healthcare industry. From this alliance, we are glad that
we can offer a larger bouquet of services to our global clientele and move closer to our vision”, said Dr. Chetan
Tamhankar, Chief Operating Officer of SIRO Clinpharm.
|
